Kac PR, González-Ortiz F, Emeršič A, Dulewicz M, Koutarapu S, Turton M, An Y, Smirnov D, Kulczyńska-Przybik A, Varma VR, Ashton NJ, Montoliu-Gaya L, Camporesi E, Winkel I, Paradowski B, Moghekar A, Troncoso JC, Lashley T, Brinkmalm G, Resnick SM, Mroczko B, Kvartsberg H, Gregorič Kramberger M, Hanrieder J, Čučnik S, Harrison P, Zetterberg H, Lewczuk P, Thambisetty M, Rot U, Galasko D, Blennow K, Karikari TK. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology. Nat Commun. 2024 Mar 23;15(1):2615. PubMed.
Recommends
Please login to recommend the paper.
Comments
Washington University
Kac and colleagues validated an immunoassay for plasma p-Tau212 in multiple clinical and autopsy cohorts. They demonstrated that their p-Tau212 antibody does not cross-react with p-Tau217. However, the results for their plasma p-Tau212 and p-Tau217 assays are very similar. Notably, differences in assay performance unrelated to the assay target (p-Tau212 versus p-Tau217) could account for small differences in the results. Models that include both p-Tau212 and p-Tau217 as predictors would be helpful to determine whether p-Tau212 adds significant value to the more commonly measured p-Tau217.
View all comments by Suzanne SchindlerMake a Comment
To make a comment you must login or register.